Medical device company DexCom (NASDAQ: DXCM) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 11.2% year on year to $1.34 billion. The company expects the full year’s revenue to be around $5.23 billion, close to analysts’ estimates. Its non-GAAP profit of $0.73 per share was 8.3% above analysts’ consensus estimates.
Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).
DexCom (DXCM) Q3 2026 highlights:
- Revenue $1.34 billion vs S&P analysts’ estimates of $1.33 billion (11.2% year-on-year growth, 1.2% beat)
- Adjusted EPS $0.73 vs S&P analysts’ estimates of $0.67 (8.3% beat)
- Adjusted EBITDA $435.2 million vs analyst estimates of $424 million (32.4% margin, 2.6% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $5.23 billion at the midpoint from $5.22 billion
- Operating margin 24.3%, up from 20.1% in the same quarter last year
- Organic revenue rose 11% year on year (beat)
- Market capitalization $30.16 billion
StockStory’s take
DexCom delivered third-quarter results that outperformed Wall Street revenue expectations, prompting a positive market reaction. Management attributed the performance to continued share gains in the U.S., robust adoption of its continuous glucose monitoring (CGM) systems, and operational improvements that expanded margins. CEO Jake Leach highlighted strong demand among type 2 diabetes patients, including those not on insulin, and cited the CONNECT study’s publication as further evidence supporting the use of CGM in broader populations. He also pointed to successful execution in manufacturing and commercial operations as key enablers of this growth.
Looking ahead, DexCom’s updated guidance is shaped by expectations for expanded coverage, new product rollouts, and the continuing impact of recent clinical data. Management believes the CONNECT study—now published in the New England Journal of Medicine—will drive coverage expansion in the U.S. and internationally, particularly for type 2 non-insulin users. CFO and COO Jereme Sylvain noted that investments in manufacturing capacity, digital support platforms, and the upcoming G7 15 Day and G8 launches are expected to support both revenue growth and operating leverage. The company sees opportunities to further expand access and improve retention as new reimbursement decisions and product enhancements roll out.
Key insights from management’s remarks
Management identified strong U.S. market share gains, broader clinical validation, and operational efficiencies as key drivers of the quarter’s outperformance.
- U.S. share gains: DexCom saw continued market share increases in the U.S., with particularly strong performance among type 2 diabetes patients not using insulin. Management credited growing physician awareness and the positive clinical profile of DexCom’s CGM technology for this trend.
- CONNECT study impact: The CONNECT randomized controlled trial, published in the New England Journal of Medicine, demonstrated significant A1C improvements for DexCom users. Management views this as a catalyst for further expanding reimbursement and clinical adoption, setting the stage for broader coverage, especially among non-insulin type 2 diabetes patients.
- Product innovation: The company launched a redesigned Stelo app to deliver more personalized glucose insights, meal logging, and nutritional data. In addition, the G7 15 Day system rollout accelerated in the U.S., with nearly 50% of the U.S. customer base expected to convert by year-end, and international launches beginning in Canada and Japan.
- Operational execution: Manufacturing efficiencies, improved freight costs, and the startup of commercial production at the Ireland facility contributed to margin expansion and enhanced supply resilience. Management emphasized the importance of these efforts in supporting future growth.
- Expansion of direct channels: DexCom announced a deal to acquire a major European distributor, enabling direct operations in high-potential markets. The launch of DexCom Direct, a support service for navigating coverage and reimbursement, is expected to help patients maintain access despite changes in payer contracts.
Drivers of future performance
DexCom’s outlook centers on expanded coverage, new product launches, and operational scaling to drive growth and sustain margins.
- Coverage expansion potential: Management expects the CONNECT study to support expanded Medicare and commercial coverage for type 2 non-insulin users, which could significantly increase the addressable market and patient starts in the coming year. The anticipated update to clinical standards is also viewed as a positive catalyst.
- Product rollout and adoption: The ongoing launch of G7 15 Day in the U.S., expansion into Canada and Japan, and further development of the G8 platform are expected to support both revenue growth and improved gross margins. Management highlighted that operational efficiencies and the scaling of the Ireland facility should mitigate start-up cost headwinds over time.
- Retention and pricing stability: The company is investing in digital support platforms and customer engagement tools to maintain strong retention rates as the user base diversifies. Management reported stable pricing environments in both the U.S. and international markets, despite competitive pressures, which is expected to support profitability.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will closely monitor (1) the pace of Medicare and commercial coverage expansion for type 2 non-insulin users following CONNECT’s publication, (2) adoption rates of the G7 15 Day and progress on the G8 platform rollout in the U.S. and internationally, and (3) execution on direct distribution initiatives in Europe. Additional focus will be placed on the integration of digital support tools and the impact of operational scaling from the Ireland facility.
DexCom currently trades at $83.87, up from $79.90 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Our favorite stocks right now
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
